Kidney Week 2020
Chronic kidney disease (CKD) is a leading public health problem worldwide. At present, only estimates based on records of patients with advanced stages of CKD are used to assess the prevalence of CKD in Mexico. L. Monserrat Perez-Navarro and colleagues conducted a cross-sectional retrospective study to identify common comorbidities associated with CKD at various disease stages.
Results of the study were reported during a virtual poster session as ASN Kidney Week 2020. The poster was titled Prevalence of Diabetes, Hypertension, Anemia, and Hyperkalemia as Frequent Comorbidities in Patients with CKD Regardless of Their KDIGO Staging.
The researchers utilized records of adult patients who received an outpatient nephrology consultation at a third level hospital from February 2019 to February 2020, with laboratory reports from 15 days prior to the inclusion date.
A total of 1772 records were included in the analysis. Mean age was 42 years, 51% (n=907) were female, and 12% were receiving renal replacement therapy (11% hemodialysis and 1% peritoneal dialysis). Most (87%, n=1546) had no family history of CKD, and 11% (n=192) were smokers. Body mass index measurements were 2% (n=32) low weight, 37% (n=562) normal weight, 53% (n=804) overweight, and 8% (n=122) obese.
The two most common comorbidities were type 2 diabetes mellitus and hypertension. The prevalence of proteinuria was 39% (n=693), 53% (n=826) had anemia, 29% (n=325) had hyperkalemia (serum potassium ≥5). The prevalence of serum albumin <3.5 g/dL was 26%, 44% had glucose >100 mg/dL, 53% had triglyceride >150 mg/dL, and 29% had total cholesterol level ≥200 mg/dL.
In summary, the researchers said, “A high prevalence of CKD comorbid risk factors such as diabetes, hypertension, anemia, and hyperkalemia were identified regardless of CKD staging, increasing in proportion in later stages.”
Source: Perez-Navarro LM, Escorza Valdivia S, Benitez Renteria AS, Valdez-Ortiz R. Prevalence of diabetes, hypertension, anemia, and hyperkalemia as frequent comorbidities in patients with CKD regardless of their KDIGO staging. Abstract of a poster presented at the American Society of Nephrology virtual Kidney Week 2020 (Abstract PO0519), October 22, 2020. Funding for this poster was supplied by AstraZeneca.